Key Highlights
- Loss per share was USD 0.01 against an estimate of a USD 1.46 loss.
- Net loss was USD 1.05 million, compared with USD 2.98 million.
- Research and development expenses were USD 271 thousand, against USD 1.52 million.
- Nine-month net loss was USD 5.38 million, against USD 12.74 million.
Indaptus Therapeutics (NASDAQ:INDP) reported a third quarter 2026 loss per share of USD 0.01, against an estimate of a USD 1.46 loss and a USD 2.98 loss in the third quarter of 2025. The net loss was USD 1,048,778, compared with USD 2,975,117.
The loss from operations was USD 1,135,867, compared with USD 2,648,487. The company reported the figures in its quarterly filing for the period ended September 30, 2026.
Operating Expenses
Research and development expenses were USD 271,204, compared with USD 1,517,723, and general and administrative expenses were USD 864,663, compared with USD 1,130,764. Total operating expenses were USD 1,135,867, compared with USD 2,648,487.
Other income, net, was USD 87,089, compared with USD 39,088. The prior-year quarter included a USD 365,718 loss from the change in Fair Value of convertible promissory notes, with none in the third quarter of 2026. Total other income, net, was USD 87,089, compared with total other expense, net, of USD 326,630.
Nine-Month Results
For the nine months ended September 30, 2026, the net loss was USD 5,384,709, compared with USD 12,736,466, and the net loss per share was USD 0.06, compared with USD 18.48. Total operating expenses were USD 5,104,319, compared with USD 11,677,809, and the loss from operations was USD 5,104,319, compared with USD 11,677,809.
Research and development expenses for the nine months were USD 1,125,465, compared with USD 6,495,677, and general and administrative expenses were USD 3,978,854, compared with USD 5,182,132. The nine-month period included a Warrant repricing expense of USD 410,154, with none in the prior-year period, and other income, net, of USD 129,764, compared with USD 94,764. The change in fair value of convertible promissory notes for the prior-year nine months was USD 1,153,421.
Per Share Information
The filing reports basic and diluted net loss per share of USD 0.01 for the quarter, compared with USD 2.98 in the prior-year quarter, and USD 0.06 for the nine months, compared with USD 18.48. It also states that diluted loss per share is based upon the weighted average number of shares of common stock outstanding, and that certain potentially dilutive securities were excluded from the calculation because their effect would have been anti-dilutive for the periods presented.
The weighted average number of shares used in calculating net loss per share is disclosed in the filing for both the quarter and the nine-month period.
The filing states that on June 17, 2026 the company entered into a stock purchase agreement under which it agreed to issue and sell 20,000,000 shares of its common stock at a purchase price of USD 0.60 per share, for aggregate gross proceeds of approximately USD 12.0 million before offering expenses. It also states that on August 28, 2026 the company entered into an amendment to its at-the-market agreement dated June 1, 2022, which supersedes and replaces that agreement, and that shares of preferred stock issued in a December 2025 offering were converted to common stock during the three months ended March 31, 2026.
Indaptus Therapeutics Q3 2026 Earnings: Key Takeaways
Indaptus Therapeutics reported a third quarter 2026 net loss of USD 1,048,778 and a loss per share of USD 0.01. Research and Development expenses were USD 271,204, compared with USD 1,517,723 in the prior-year quarter.






Please wait processing your request...